Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5

ABSTRACT Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS), in combination with proteolytic protection assays, has been used to identify the functional epitope on human immunodeficiency virus envelope glycoprotein gp41 for the broadly neutralizing anti-gp41 human monoclonal antibody 2F5. In this protection assay-based procedure, a soluble gp140 protein with a stabilizing intermolecular disulfide bond between the gp120 and gp41 subunits (SOS gp140) was affinity bound to immobilized 2F5 under physiological conditions. A combination of proteolytic enzymatic cleavages was then performed to remove unprotected residues. Residues of SOS gp140 protected by their binding to 2F5 were then identified based on their molecular weights as determined by direct MALDI-MS of the immobilized antibody beads. The epitope, NEQELLELDKWASLWN, determined by this MALDI-MS protection assay approach consists of 16 amino acid residues near the C terminus of gp41. It is significantly longer than the ELDKWA core epitope previously determined for 2F5 by peptide enzyme-linked immunosorbent assay. This new knowledge of the structure of the 2F5 epitope may facilitate the design of vaccine antigens intended to induce antibodies with the breadth and potency of action of the 2F5 monoclonal antibody.

[1]  S. Zolla-Pazner,et al.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.

[2]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[3]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[4]  A. Trkola,et al.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.

[5]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[6]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[7]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[8]  E. Emini,et al.  Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Zolla-Pazner,et al.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.

[10]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[11]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[12]  Q. Sattentau,et al.  Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.

[13]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[14]  A. Trkola,et al.  Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.

[15]  C. Barbas,et al.  Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. , 1996, AIDS research and human retroviruses.

[16]  A. Trkola,et al.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.

[17]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[18]  D. Burton.  A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Burton,et al.  The antibody response in HIV-1 infection. , 1997, AIDS.

[20]  C. Burrell,et al.  Enhancement or inhibition of HIV‐1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription , 1997, AIDS.

[21]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[22]  S. Rowland-Jones,et al.  Role of cellular immunity in protection against HIV infection. , 1997, Advances in immunology.

[23]  Dennis R. Burton,et al.  Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.

[24]  N. Letvin.  Progress in the development of an HIV-1 vaccine. , 1998, Science.

[25]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[26]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[27]  D. Baltimore,et al.  HIV Vaccines—where are we going? , 1998, Nature Medicine.

[28]  D. Montefiori,et al.  Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.

[29]  E. Hunter,et al.  A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.

[30]  Q. Sattentau,et al.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.

[31]  D. Montefiori,et al.  Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. , 1999, AIDS research and human retroviruses.

[32]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[33]  S. Zolla-Pazner,et al.  Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A1 , 2000, The Journal of Immunology.

[34]  Y. Xiao,et al.  Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine. , 2000, Hybridoma.

[35]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[36]  Ying-hua Chen,et al.  Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine☆ , 2000, Peptides.

[37]  Ying-hua Chen,et al.  Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines against HIV–1 , 2000, International Archives of Allergy and Immunology.

[38]  Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1. , 2000, Immunobiology.

[39]  J. Binley,et al.  Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.

[40]  Lǔ,et al.  Multiepitope Vaccines Intensively Increased Levels of Antibodies Recognizing Three Neutralizing Epitopes on Human Immunodeficiency Virus‐1 Envelope Protein , 2000, Scandinavian journal of immunology.

[41]  S. Zolla-Pazner,et al.  Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41 , 2000, Journal of Virology.

[42]  Ying-hua Chen,et al.  Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope ELDKWA and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines against HIV-1 , 2000, International Archives of Allergy and Immunology.

[43]  K. Tomer,et al.  Epitope mapping by a combination of epitope excision and MALDI-MS. , 2000, Methods in molecular biology.

[44]  C Leclerc,et al.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.

[45]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[46]  B. Moss,et al.  Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge , 2000, Journal of Virology.

[47]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[48]  Ying-hua Chen,et al.  Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody , 2000, Immunological investigations.

[49]  A structure-based approach to a synthetic vaccine for HIV-1. , 2000, Biochemistry.

[50]  Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. , 2000, FEMS immunology and medical microbiology.

[51]  J. Binley,et al.  A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.

[52]  K. Tomer,et al.  A general strategy for epitope mapping by direct MALDI-TOF mass spectrometry using secondary antibodies and cross-linking. , 2001, Analytical chemistry.

[53]  B. Moss,et al.  Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys , 2001, Journal of Virology.

[54]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[55]  S. Rowland-Jones,et al.  Cellular immune responses to HIV , 2001, Nature.

[56]  Y. Xiao,et al.  ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41. , 2001, Immunology letters.

[57]  James G. Herndon,et al.  Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.

[58]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[59]  R. Steinman,et al.  Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+ T-Cell Responses from Chronically Infected Individuals , 2001, Journal of Virology.

[60]  G. Nabel.  Challenges and opportunities for development of an AIDS vaccine , 2001, Nature.

[61]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.